The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 11, 2017

Filed:

Jan. 21, 2015
Applicant:

Nabriva Therapeutics Ag, Vienna, AT;

Inventors:

Klaus Thirring, Vienna, AT;

Werner Heilmayer, Zillingtal, AT;

Rosemarie Riedl, Vienna, AT;

Hermann Kollmann, Linz, AT;

Zrinka Ivezic-Schoenfeld, Korneuburg, AT;

Wolfgang Wicha, Bruck an der Leitha, AT;

Susanne Paukner, Vienna, AT;

Dirk Strickmann, Purkersdorf, AT;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 323/52 (2006.01); A61K 31/22 (2006.01); A61K 31/4409 (2006.01); A61K 31/445 (2006.01); A61K 31/4465 (2006.01); A61K 31/495 (2006.01); A61K 31/52 (2006.01); C07C 323/62 (2006.01); C07D 211/26 (2006.01); C07D 295/13 (2006.01); C07D 211/54 (2006.01); C07D 211/58 (2006.01); C07D 295/192 (2006.01); C07D 213/36 (2006.01); C07D 213/40 (2006.01); C07D 213/70 (2006.01); C07D 223/06 (2006.01); C07D 473/24 (2006.01); C07D 211/20 (2006.01); A61K 31/216 (2006.01); A61K 31/4196 (2006.01); A61K 31/44 (2006.01); A61K 31/4458 (2006.01); A61K 31/4468 (2006.01); A61K 31/5375 (2006.01); C07D 213/32 (2006.01); C07D 213/56 (2006.01); C07D 249/14 (2006.01); C07D 473/38 (2006.01);
U.S. Cl.
CPC ...
C07C 323/52 (2013.01); A61K 31/216 (2013.01); A61K 31/22 (2013.01); A61K 31/4196 (2013.01); A61K 31/44 (2013.01); A61K 31/445 (2013.01); A61K 31/4409 (2013.01); A61K 31/4458 (2013.01); A61K 31/4465 (2013.01); A61K 31/4468 (2013.01); A61K 31/495 (2013.01); A61K 31/52 (2013.01); A61K 31/5375 (2013.01); C07C 323/62 (2013.01); C07D 211/20 (2013.01); C07D 211/26 (2013.01); C07D 211/54 (2013.01); C07D 211/58 (2013.01); C07D 213/32 (2013.01); C07D 213/36 (2013.01); C07D 213/40 (2013.01); C07D 213/56 (2013.01); C07D 213/70 (2013.01); C07D 223/06 (2013.01); C07D 249/14 (2013.01); C07D 295/13 (2013.01); C07D 295/192 (2013.01); C07D 473/24 (2013.01); C07D 473/38 (2013.01); C07C 2101/02 (2013.01); C07C 2101/14 (2013.01); C07C 2103/82 (2013.01);
Abstract

A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula processes for the preparation of such compounds and their use as pharmaceuticals.


Find Patent Forward Citations

Loading…